A unique cell surface antigen identifying lymphoid malignancies of B cell origin.

Abstract

A B S T R A C T A monoclonal antibody (anti-B 1) specific for a unique B cell surface differentiation antigen was used to characterize the malignant cells from patients with leukemias or lymphomas. All tumor cells from patients with lymphomas or chronic lymphocytic leukemias, bearing either monoclonal K or X light chain, expressed the Bl antigen. In contrast, tumor cells from T cell leukemias and lymphomas or acute myeloblastic leukemias were unreactive. Approximately 50% of acute lymphoblastic leukemias (ALL) of non-T origin and 50% of chronic myelocytic leukemia in blast crisis were also anti-Bl reactive. Moreover, 21 of 28 patients with the common ALL antigen (CALLA) positive form of ALL were anti-B1 positive, whereas 0 of 13 patients with CALLA negative ALL were reactive.These observations demonstrate that an antigen present on normal B cells is expressed on the vast majority of B cell lymphomas and on -75% of CALLA positive ALL, suggesting that these tuimors may share a common B cell lineage.

An Epstein-Barr virus-negative B lymphoma cell line (THP-2) from a Burkitt's lymphoma of a Japanese patient.

“…In addition, THP-2 cells were positive for Ia-like antigen, common ALL antigen (J5) and human B cell specific antigen (B1) on their surface. Bl antigen, known to be a unique B cell surface differentiation antigen, was positive in all B cell lymphoma cells reported (Nadler et al 1981). On the other hand, the expression of common ALL antigen, which permits classification of B cell lines, has not always occurred on the Burkitt's lymphoma cells; these were common ALL positive "B-blast I" and common ALL negative "B-blast II", which are considered to be in different differentiation stages (Minowada et al 1981).…”

Radioimmunotherapy for Non-Hodgkin Lymphoma : Historical Perspective and Current Status

“…131 I-T (Bexxar TM ) uses the B1 anti-CD20 antibody first developed by Nadler et al 27 and is currently available in the USA. These products will be discussed in details below.…”

Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia

“…6,7 rituximab has been shown to result in a depletion of the B lymphocyte pool in vivo. 8 Although rituximab has been demonstrated to be an active therapeutic agent for the treatment of relapsed or refractory low-grade B cell non-Hodgkin's lymphoma, recently there have been reports of its efficacy in the treatment of B cell CLL.…”